SGLT2 inhibitors represent one of the most remarkable therapeutic developments in heart failure care, transitioning from ...

The final thesis of Professor Lim Soo's team of the Department of Endocrine Metabolism at Bundang Seoul National University ...

Patients with AAV and kidney involvement who take SGLT-2 inhibitors may have a reduced risk for ESRD and kidney transplant ...

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases.

SGLT2 inhibitors were associated with greater reduction in MACE risk among older adults than younger adults with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer a greater ...

Patients with asthma and T2 diabetes using SGLT2 inhibitors have a significantly decreased mortality risk within 30 days of an asthma exacerbation.

SAN DIEGO — Patients with cirrhosis treated with sodium-glucose cotransporter 2 (SGLT2) inhibitors show significant reductions in a range of portal hypertension complications and all-cause mortality ...

Please provide your email address to receive an email when new articles are posted on . Most patients who qualify for an SGLT2 inhibitor are not prescribed one. Prescription rates for those with a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Use of sodium-glucose cotransporter 2 inhibitors was ...

For the first time, researchers said SGLT2 inhibitors may have some disease-modifying potential for nonsevere aortic stenosis ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 ...

SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients, highlighting ...